News
TVRD
1.180
+2.16%
0.025
Analysts’ Top Healthcare Picks: Tvardi Therapeutics (TVRD), BioCardia (BCDA)
TipRanks · 17h ago
Tvardi Q3 Loss Widens On Higher Clinical Costs; Liver Cancer Data Due Early Q1 2027
NASDAQ · 23h ago
Tvardi Therapeutics reports Q3 EPS (48c), consensus (57c)
TipRanks · 1d ago
Tvardi Therapeutics Q3 EPS $(0.48) Beats $(0.53) Estimate
Benzinga · 1d ago
Tvardi Therapeutics GAAP EPS of -$0.48 beats by $0.01
Seeking Alpha · 1d ago
*Tvardi Therapeutics 3Q Loss $6.12M >TVRD
Dow Jones · 1d ago
Press Release: Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
Dow Jones · 1d ago
Press Release: Tvardi Therapeutics Announces -2-
Dow Jones · 1d ago
Tvardi: Q3 Earnings Snapshot
Barchart · 1d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 4d ago
Weekly Report: what happened at TVRD last week (1102-1106)?
Weekly Report · 5d ago
TTI-109’s Targeted STAT3 Inhibition and Potential Safety Advantages Support a Buy Rating
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Tvardi Therapeutics (TVRD)
TipRanks · 11/04 09:30
Weekly Report: what happened at TVRD last week (1026-1030)?
Weekly Report · 11/02 10:16
Weekly Report: what happened at TVRD last week (1019-1023)?
Weekly Report · 10/26 10:16
Tvardi Therapeutics Price Target Announced at $8.00/Share by Chardan Capital
Dow Jones · 10/20 12:06
Tvardi Therapeutics Initiated at Buy by Chardan Capital
Dow Jones · 10/20 12:06
Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga · 10/20 11:56
Tvardi Therapeutics initiated with a Buy at Chardan
TipRanks · 10/20 10:56
Weekly Report: what happened at TVRD last week (1012-1016)?
Weekly Report · 10/19 10:16
More
Webull provides a variety of real-time TVRD stock news. You can receive the latest news about Tvardi Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.